perfluorophenyl 3-(2-(2-(1,3-dioxoisoindolin-2-yloxy)ethoxy)ethoxy)propanoate

Perfluorophenyl 3-(2-(2-(1,3-dioxoisoindolin-2-yloxy)ethoxy)ethoxy)propanoate is a specialized ADC linker reagent designed for the construction of advanced antibody-drug conjugates (ADCs) and precision bioconjugation applications. As an effective ADC linker, it enables site-specific conjugation between monoclonal antibodies and diverse ADC cytotoxins, facilitating controlled and targeted delivery of therapeutic payloads to tumor cells. Its chemical structure combines a perfluorophenyl ester for reactive conjugation with a phthalimide-protected triethylene glycol spacer, providing both aqueous solubility and flexibility. In ADC linker design, this compound supports modular bioconjugation strategies that maintain antibody integrity while enabling efficient intracellular release of ADC payloads in the tumor microenvironment.

In ADC payload applications, this linker is compatible with a wide range of cytotoxins, including microtubule inhibitors, DNA-targeting agents, and other potent ADC payloads. The perfluorophenyl ester facilitates selective reaction with primary amine groups on antibodies, allowing reproducible and homogeneous conjugation. Its triethylene glycol spacer reduces steric hindrance and enhances linker flexibility, improving pharmacokinetic properties and stability of ADCs. By employing this ADC linker, researchers can precisely control the attachment of payloads, optimize release kinetics, and preserve antigen-binding specificity, supporting high-performance targeted therapies.

From an application perspective, this linker is widely utilized in oncology-focused ADC research, targeted drug delivery systems, and bioconjugation studies. Its chemical versatility enables cleavable or non-cleavable linker strategies depending on therapeutic goals. The reagent’s aqueous solubility and predictable reactivity allow efficient conjugation under mild conditions while maintaining antibody function. Its combination of site-specific reactivity, structural flexibility, and compatibility with diverse ADC cytotoxins makes it a valuable tool in the development of next-generation antibody-drug conjugates with enhanced tumor specificity and optimized therapeutic outcomes.